Skip Navigation



JAC Advance Access published online on January 14, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg102
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/2/347    most recent
dkg102v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eldere, J. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eldere, J. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Original article

Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections

J. Van Eldere 1*

1 Rega Institute and Laboratory of Microbiology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium

* Corresponding author. E-mail: johan.vaneldere{at}uz.kuleuven.ac.be.

Received 18 September 2002 ; revised 23 October 2002 ; accepted 26 November 2002

Abstract

Objectives: To determine susceptibility rates and patterns in Pseudomonas aeruginosa strains isolated from nosocomial infections.

Methods: Seven hundred and sixteen P. aeruginosa isolates from 40 different hospitals in Belgium and the Grand Duchy of Luxembourg were collected in 1999.

Results: Resistance rates varied significantly between hospitals. Of the fluoroquinolones, ciprofloxacin showed least resistance (24%), levofloxacin showed 27.5% resistance and ofloxacin 37.5%. Of the aminoglycosides, amikacin was the most potent antibiotic (10.5% resistance), followed by isepamicin (12%), tobramycin (19.5%) and gentamicin (23.5%). Of the {beta}-lactam antibiotics, meropenem was the most active (9.5% resistance); piperacillin and piperacillin/tazobactam had, respectively, 24% and 17.5% resistance, ceftazidime 28.5%, cefepime 29.5%, ticarcillin/clavulanic acid 37% and aztreonam 55.5%. MIC distribution curves show the presence of significant subpopulations, with MICs just below breakpoint for many antibiotics.

Conclusion: Resistance of P. aeruginosa to penicillins, cephalosporins, fluoroquinolones and aminoglycosides varies between hospitals, but is increasing.

Keywords: Pseudomonas aeruginosa, nosocomial infections, susceptibility rates, surveillance
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
N. Aoki, K. Tateda, Y. Kikuchi, S. Kimura, C. Miyazaki, Y. Ishii, Y. Tanabe, F. Gejyo, and K. Yamaguchi
Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa
J. Antimicrob. Chemother., March 1, 2009; 63(3): 534 - 542.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. S. Kaye, Z. A. Kanafani, A. E. Dodds, J. J. Engemann, S. G. Weber, and Y. Carmeli
Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2192 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. Hocquet, P. Nordmann, F. El Garch, L. Cabanne, and P. Plesiat
Involvement of the MexXY-OprM Efflux System in Emergence of Cefepime Resistance in Clinical Strains of Pseudomonas aeruginosa.
Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1347 - 1351.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia
Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 388 - 416.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Poole
Aminoglycoside Resistance in Pseudomonas aeruginosa
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 479 - 487.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.